IXICO (LSE:IXI) Debt-to-Equity : 0.03 (As of Sep. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IXICO Debt-to-Equity?

IXICO's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £0.11 Mil. IXICO's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was £0.28 Mil. IXICO's Total Stockholders Equity for the quarter that ended in Sep. 2023 was £11.43 Mil. IXICO's debt to equity for the quarter that ended in Sep. 2023 was 0.03.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for IXICO's Debt-to-Equity or its related term are showing as below:

LSE:IXI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.04 Max: 0.05
Current: 0.03

During the past 13 years, the highest Debt-to-Equity Ratio of IXICO was 0.05. The lowest was 0.02. And the median was 0.04.

LSE:IXI's Debt-to-Equity is ranked better than
80.95% of 1071 companies
in the Biotechnology industry
Industry Median: 0.15 vs LSE:IXI: 0.03

IXICO Debt-to-Equity Historical Data

The historical data trend for IXICO's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IXICO Debt-to-Equity Chart

IXICO Annual Data

Trend

Sep13

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.05

0.04

0.03

IXICO Semi-Annual Data
	Sep13	Mar14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.05	0.05	0.04	0.04	0.03

Competitive Comparison of IXICO's Debt-to-Equity

For the Biotechnology subindustry, IXICO's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IXICO's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IXICO's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where IXICO's Debt-to-Equity falls into.

IXICO Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

IXICO's Debt to Equity Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.112	+	0.275)	/	11.432
	=	0.03

IXICO's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.112	+	0.275)	/	11.432
	=	0.03

IXICO (LSE:IXI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

IXICO Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of IXICO's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

IXICO (LSE:IXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IXICO PLC (LSE:IXI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PHYOF:USA

Address

15 Long Lane, 4th Floor, Griffin Court, London, GBR, EC1A 9PN

Website

https://www.ixico.com

IXICO PLC is a UK-based company engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies. Its therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, Progressive Supranuclear Palsy, and Other Rare Neurological Diseases. Services offered by the company are Early Phase Clinical Development, Late Phase Clinical Development, Post-Marketing, and Consultancy. The company's geographical segments include the United States, Switzerland, the United Kingdom, the Netherlands, Ireland and other- Europe. The Company work with healthcare organizations across the entire clinical research journey, for drug development analytics, medical imaging operations and post-marketing surveillance.

IXICO (LSE:IXI) Headlines

No Headlines